Status:
ACTIVE_NOT_RECRUITING
Nicotinamide Riboside Impact on Extracellular Nicotinamide Adenine Dinucleotide (NAD+)
Lead Sponsor:
Charite University, Berlin, Germany
Collaborating Sponsors:
ChromaDex, Inc.
Conditions:
NAD
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The investigation is a clinical study in which the impact of taking the dietary supplement nicotinamide riboside (NR) on the concentration of extracellular nicotinamide adenine dinucleotide (eNAD+) in...
Detailed Description
The significance of nicotinamide adenine dinucleotide (NAD+) in promoting a healthy life is currently under intense research. Despite an increasing number of research groups focusing on NAD+, there is...
Eligibility Criteria
Inclusion
- Good general health
- Normal nutritional status and
- Age \>18 years.
Exclusion
- Pregnancy and/or lactation, or
- Severe psychiatric disorders, or
- Conditions that involve attention deficits, or
- Severe medical conditions, or
- Withdrawal of consent by the participant.
Key Trial Info
Start Date :
November 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT06005350
Start Date
November 1 2023
End Date
December 31 2024
Last Update
June 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Surgical Clinic, Campus Virchow-Klinikum / Campus Charité Mitte, Charité - Universitätsmedizin Berlin
Berlin, Germany, 13353